Περίληψη:
Background Brentuximab vedotin (BV) was approved as a therapy for
mycosis fungoides (MF) based on the ALCANZA trial. Little real-world
data, however, are available. Objectives To evaluate the efficacy and
safety of BV in patients with MF/Sezary Syndrome (SS) with variable CD30
positivity in a real-world cohort and to explore potential predictors of
response. Methods Data from 72 patients with MF/SS across nine EORTC
(European Organization for Research and Treatment of Cancer) centres
were included. The primary endpoint was to evaluate the proportion of
patients with: overall response (ORR), ORR lasting over 4 months (ORR4),
time to response (TTR), response duration (RD), progression-free
survival (PFS) and time to next treatment (TTNT). Secondary aims
included a safety evaluation and the association of clinicopathological
features with ORR, RD and TTNT. Results All 72 patients had received at
least one systemic treatment. ORR was achieved in 45 of 67; ORR4 in 28
of 67 with a median TTR of 8 weeks [interquartile range (IQR) 5 center
dot 5-14] and with a median RD of 9 months (IQR 3 center dot 4-14).
Median PFS was 7 months (IQR 2-12) and median TTNT was 30 days (6-157
center dot 5). Patient response, RD, PFS and TTNT were not associated
with any clinicopathological characteristics. In the MF group, patients
with stage IIB/III vs. IV achieved longer PFS and had a higher
percentage of ORR4. There was a statistically significant association
between large-cell transformation and skin ORR (P = 0 center dot 03).
ORR4 was more frequently achieved in patients without lymph node
involvement (P = 0 center dot 04). Conclusions BV is an effective option
for patients with MF/SS, including those with variable CD30 positivity,
large-cell transformation, SS, longer disease duration and who have been
treated previously with several therapies.
Συγγραφείς:
Papadavid, E.
Kapniari, E.
Pappa, V.
Nikolaou, V. and
Iliakis, T.
Dalamaga, M.
Jonak, C.
Porkert, S.
Engelina,
S.
Quaglino, P.
Ortiz-Romero, P. L.
Vico, C.
Cozzio, A.
and Dimitriou, F.
Guiron, R.
Guenova, E.
Hodak, E. and
Bagot, M.
Scarisbrick, J.
